Implementation of a novel digital diagnostic tool to support the assessment of respiratory disease in a COVID-19 fever clinic
A. Ladhams, Shrawan Patel, Mathew Çetin
求助PDF
{"title":"Implementation of a novel digital diagnostic tool to support the assessment of respiratory disease in a COVID-19 fever clinic","authors":"A. Ladhams, Shrawan Patel, Mathew Çetin","doi":"10.1136/bmjinnov-2021-000673","DOIUrl":null,"url":null,"abstract":"© Author(s) (or their employer(s)) 2022. Reuse permitted under CC BYNC. No commercial reuse. See rights and permissions. Published by BMJ. INTRODUCTION Following its first detection in Wuhan, China, in December 2019, the speed at which SARSCoV2 spread around the globe took many countries and their health systems by surprise. The coronavirus pandemic presented three major difficulties, namely a surge in SARSCoV2 infections, high mortality associated with COVID19 disease and large patient numbers overwhelming emergency departments and intensive care units. In March 2020, the Australian government responded by establishing standalone fever clinics to assess patients experiencing symptoms possibly related to COVID19. At a macro level, these clinics helped Australia manage many aspects of the pandemic; however, at a micro level, the clinics encountered various challenges. First, SARSCoV2 spread through the population alongside other winterassociated respiratory illnesses causing a surge in the volume of individuals experiencing COVID19like symptoms, and thus presenting to the clinics. Second, the precautionary requirement for clinicians to don and doff personal protective equipment between patient encounters reduced patient assessment speed and efficiency. Finally, given that the symptoms of respiratory illnesses—including fever, cough, sore throat and shortness of breath—can be related to a number of different diseases such as COVID19, chronic obstructive pulmonary disease (COPD), asthma, pneumonia and upper respiratory tract infections, there is diagnostic complexity in distinguishing patients with a particular respiratory disease and even more so for those with concurrent infections. This final challenge is exaggerated in highthroughput clinical environments, such as COVID19 fever clinics. A single Federal Government funded COVID19 fever clinic in Queensland, Australia, looked to virtual health technologies as a potential way to alleviate these problems. One technology in particular—ResAppDx (‘the device’)—offered noticeable value to the COVID19 fever clinic due to its ability to rapidly identify Summary box","PeriodicalId":53454,"journal":{"name":"BMJ Innovations","volume":"49 1","pages":"55 - 59"},"PeriodicalIF":1.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Innovations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjinnov-2021-000673","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 1
引用
批量引用
Abstract
© Author(s) (or their employer(s)) 2022. Reuse permitted under CC BYNC. No commercial reuse. See rights and permissions. Published by BMJ. INTRODUCTION Following its first detection in Wuhan, China, in December 2019, the speed at which SARSCoV2 spread around the globe took many countries and their health systems by surprise. The coronavirus pandemic presented three major difficulties, namely a surge in SARSCoV2 infections, high mortality associated with COVID19 disease and large patient numbers overwhelming emergency departments and intensive care units. In March 2020, the Australian government responded by establishing standalone fever clinics to assess patients experiencing symptoms possibly related to COVID19. At a macro level, these clinics helped Australia manage many aspects of the pandemic; however, at a micro level, the clinics encountered various challenges. First, SARSCoV2 spread through the population alongside other winterassociated respiratory illnesses causing a surge in the volume of individuals experiencing COVID19like symptoms, and thus presenting to the clinics. Second, the precautionary requirement for clinicians to don and doff personal protective equipment between patient encounters reduced patient assessment speed and efficiency. Finally, given that the symptoms of respiratory illnesses—including fever, cough, sore throat and shortness of breath—can be related to a number of different diseases such as COVID19, chronic obstructive pulmonary disease (COPD), asthma, pneumonia and upper respiratory tract infections, there is diagnostic complexity in distinguishing patients with a particular respiratory disease and even more so for those with concurrent infections. This final challenge is exaggerated in highthroughput clinical environments, such as COVID19 fever clinics. A single Federal Government funded COVID19 fever clinic in Queensland, Australia, looked to virtual health technologies as a potential way to alleviate these problems. One technology in particular—ResAppDx (‘the device’)—offered noticeable value to the COVID19 fever clinic due to its ability to rapidly identify Summary box
实施一种新型数字诊断工具,以支持COVID-19发烧诊所的呼吸道疾病评估
©作者(或其雇主)2022。在CC BYNC下允许重用。禁止商业重用。请参阅权利和权限。英国医学杂志出版。自2019年12月在中国武汉首次发现sars病毒以来,sars病毒在全球传播的速度令许多国家及其卫生系统感到意外。冠状病毒大流行带来了三大困难,即sars病毒感染激增、与covid - 19疾病相关的高死亡率以及急诊和重症监护病房的大量患者。2020年3月,澳大利亚政府采取了应对措施,建立了独立的发烧诊所,以评估可能出现与covid - 19相关症状的患者。在宏观层面上,这些诊所帮助澳大利亚管理了大流行病的许多方面;然而,在微观层面上,诊所遇到了各种各样的挑战。首先,sars - v2与其他冬季相关的呼吸系统疾病一起在人群中传播,导致出现covid - 19样症状的人数激增,从而到诊所就诊。其次,临床医生在病人接触之间穿脱个人防护装备的预防性要求降低了病人评估的速度和效率。最后,考虑到呼吸道疾病的症状——包括发烧、咳嗽、喉咙痛和呼吸短促——可能与许多不同的疾病有关,如covid - 19、慢性阻塞性肺疾病(COPD)、哮喘、肺炎和上呼吸道感染,因此,在区分患有特定呼吸道疾病的患者时存在诊断复杂性,对于并发感染的患者更是如此。在高通量的临床环境中,如covid - 19发烧诊所,最后的挑战被夸大了。澳大利亚昆士兰州一家由联邦政府资助的covid - 19发烧诊所将虚拟卫生技术视为缓解这些问题的潜在方法。其中一项技术——resappdx(“设备”)——由于能够快速识别摘要框,为covid - 19发烧诊所提供了显著的价值
本文章由计算机程序翻译,如有差异,请以英文原文为准。